Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

498
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
498
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

305
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
305
Dementia01:30

Dementia

285
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
285
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory alterations mediate tau-associated neurodegeneration.

Brain communications·2026
Same author

Predictors of Incident Dementia in a Cohort of Elders with Essential Tremor: A Prospective, Longitudinal Study.

Neuro-degenerative diseases·2026
Same author

The Role of Apathy in the Association Between Depressive Symptoms and Subjective Cognitive Complaints.

International journal of geriatric psychiatry·2026
Same author

Biomarkers of angiogenesis in Alzheimer's disease: Systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026
Same author

Cueing to facilitate naming in MAPT-associated behavioral variant frontotemporal dementia: a preliminary report.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2026
Same author

The Montreal Cognitive Assessment at the Framingham Heart Study: A Re-Examination of the Norms.

Brain and behavior·2026
Same journal

Disruptions of the diffusion tensor image analysis along the perivascular space index and dynamic functional connectivity across the Alzheimer's disease spectrum: Implications for cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
Same journal

HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia.

Journal of Alzheimer's disease : JAD·2026
Same journal

The role of organochlorine pesticides as environmental factors in Alzheimer's disease in human studies: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026
Same journal

Plasma profiling of B lymphocyte-associated cytokines in Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same journal

Diluting the signal: Class-level pooling and the ecological fallacy in meta-analyses of anti-amyloid monoclonal antibodies.

Journal of Alzheimer's disease : JAD·2026
Same journal

Gut microbiota alterations in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.5K

Optimizing Subjective Cognitive Decline to Detect Early Cognitive Dysfunction.

Silvia Chapman1,2, Preeti Sunderaraman1,3,2,4, Jillian L Joyce1,3

  • 1Cognitive Neuroscience Division, Columbia University Medical Center, New York, NY, USA.

Journal of Alzheimer'S Disease : JAD
|March 1, 2021
PubMed
Summary
This summary is machine-generated.

Subjective cognitive decline (SCD) measurement matters for detecting early Alzheimer's disease (AD). Age-anchored SCD effectively identifies cognitive dysfunction, unlike general or retrospective SCD measures.

Keywords:
Cognitive dysfunctionmeasurementneuropsychological testspreclinical Alzheimer’s diseasesubjective cognitive declinetask-specific factors

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

13.9K

Related Experiment Videos

Last Updated: Nov 15, 2025

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.5K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

13.9K

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Psychology

Background:

  • Subjective cognitive decline (SCD) is a potential early indicator of preclinical Alzheimer's disease (AD).
  • However, its association with objective cognitive performance is inconsistent, limiting its utility.
  • This variability may stem from different methods used to measure SCD.

Purpose of the Study:

  • To investigate how different methods of measuring SCD influence its association with early cognitive dysfunction.
  • To determine if specific SCD measurement techniques are more effective in identifying preclinical AD.

Main Methods:

  • 110 cognitively healthy older adults completed SCD questionnaires.
  • SCD was measured in three ways: general complaints, retrospective comparison (vs. 5 years ago), and age-anchored comparison (vs. peers).
  • Participants also completed cognitive tasks assessing associative memory, short-term memory binding, and list learning.

Main Results:

  • Age-anchored SCD was reported less frequently than retrospective SCD.
  • Ordinal age-anchored SCD demonstrated significant associations with short-term memory binding, associative memory, and list learning.
  • Retrospective and general SCD measures were associated with associative memory and list learning, but not short-term memory binding.

Conclusions:

  • Ordinal age-anchored subjective cognitive decline measurement is a more suitable method for detecting early cognitive dysfunction.
  • This approach shows greater promise in identifying individuals with preclinical Alzheimer's disease compared to other SCD measurement strategies.